Brian Shuch

ORCID: 0000-0003-2065-3570

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.6Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing

Cancer(2021)10.1002/cncr.33997

Top 21%

0.973DataRank

Top 21%31 citations

Kathryn E. Hatchell, Sarah M. Nielsen, Edward D. Esplin, Karen Ouyang, Keith Nykamp +8 more

Papers

Driven by 34 papers — median percentile 73. Top paper: “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial”.

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet(2021)10.1016/s0140-6736(21)00152-5

N/A

6.9DataRank · unranked

283 citations

Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng +15 more

Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer

Cancer(2020)10.1002/cncr.32914

N/A

2.1DataRank · unranked

44 citations

Shantao Li, Harvey A. Risch, Ranjit S. Bindra, Patrick D. McGillivray, Mark Gerstein +1 more

Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

The Lancet Oncology(2024)10.1016/s1470-2045(24)00211-0

N/A

1.9DataRank · unranked

86 citations

Se-Eun Kim, Viraj A. Master, David H. McDermott, Lauren C. Harshman, Suzanne Cole +40 more

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)00913-3

N/A

1.4DataRank · unranked

49 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +14 more

Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions

Nature Genetics(2024)10.1038/s41588-024-01725-7

N/A

0.987DataRank · unranked

51 citations

Diptavo Dutta, Mitchell J. Machiela, Bryan R. Gorman, Timothy Winter, Dayne Okuhara +95 more

Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing

Cancer(2021)10.1002/cncr.33997

Top 21%

0.973DataRank

Top 21%31 citations

Kathryn E. Hatchell, Sarah M. Nielsen, Edward D. Esplin, Karen Ouyang, Keith Nykamp +8 more

Testicular Cancer, Version 2.2015

Journal of the National Comprehensive Cancer Network(2015)10.6004/jnccn.2015.0092

N/A

0.732DataRank · unranked

131 citations

Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger +27 more

Fumarate Hydratase Variants and Their Association With Paraganglioma/Pheochromocytoma

Urology(2023)10.1016/j.urology.2022.11.053

Top 33%

0.592DataRank

Top 33%10 citations

Eric Lu, Paul C. Boutros, Liying Zhang, Avital Harari, Kathryn E. Hatchell +8 more

Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier

European Urology(2020)10.1016/j.eururo.2020.09.017

N/A

0.494DataRank · unranked

26 citations

Daiki Ueno, Aydin Pooli, Neil Mendhiratta, Jamil Syed, Kevin A. Nguyen +6 more

Transcriptome- and proteome-wide association studies identify genes associated with renal cell carcinoma

The American Journal of Human Genetics(2024)10.1016/j.ajhg.2024.07.012

N/A

0.437DataRank · unranked

10 citations

Xinyu Guo, Timothy Winter, Om Jahagirdar, Mark P. Purdue, Mitchell J. Machiela +93 more

ELOC-Mutated Renal Cell Carcinoma is a Rare Indolent Tumor With Distinctive Genomic Characteristics

Modern Pathology(2025)10.1016/j.modpat.2025.100777

N/A

0.396DataRank · unranked

13 citations

Rong Rong Huang, Brian Cone, Sung‐Hae Kang, Reza Setoodeh, Anthony Sisk +5 more

Persistent racial disparities in refusal of resection in non-small cell lung cancer patients at high-volume and Black-serving institutions

Surgery(2023)10.1016/j.surg.2023.09.006

N/A

0.373DataRank · unranked

11 citations

Sara Sakowitz, Nikhil Chervu, Corynn Branche, Brian Shuch, Peyman Benharash +2 more

PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5101

N/A

0.330DataRank · unranked

8 citations

Mäneka Puligandla, Mohamad E. Allaf, David F. McDermott, Charles G. Drake, Sabina Signoretti +15 more

NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion

Molecular Cancer Research(2024)10.1158/1541-7786.mcr-23-1003

N/A

0.282DataRank · unranked

5 citations

Karlie N. Lucas, Sateja Paradkar, Joseph Edmonds, Sam Friedman, Matthew A. Murray +12 more

Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4546

N/A

0.193DataRank · unranked

2 citations

Catherine M. Tangen, Christopher W. Ryan, Ulka N. Vaishampayan, Brian Shuch, Pedro C. Barata +7 more

Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma

British Journal of Urology(2024)10.1111/bju.16403

N/A

0.104DataRank · unranked

1 citations

Catherine M. Tangen, Melissa Plets, Xiaochen Li, Maria Tretiakova, Peter A. Humphrey +11 more

Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4541

N/A

0.104DataRank · unranked

1 citations

Se Eun Kim, David F. McDermott, Viraj A. Master, Sabina Signoretti, Mahmut Akgül +13 more

Using Mendelian randomization to investigate etiologic heterogeneity across renal cell carcinoma subtypes

International Journal of Epidemiology(2025)10.1093/ije/dyaf177

N/A

0.104DataRank · unranked

1 citations

Om Jahagirdar, Mark P. Purdue, Diptavo Dutta, Mitchell J. Machiela, Bryan R. Gorman +94 more

Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4562

N/A

0DataRank · unranked

1 citations

Catherine M. Tangen, Xiaochen Li, Maria Tretiakova, Peter A. Humphrey, Adebowale Adeniran +9 more

Data from Genomic Heterogeneity and the Small Renal Mass

(2023)10.1158/1078-0432.c.6527436.v1

N/A

0DataRank · unranked

0 citations

Zuoquan Xie, Marta Boeke, Jamil Syed, Kevin Nguyen, Patrick D. McGillivray +8 more

Social determinants as predictors of resection and long-term mortality in Black patients with non-small cell lung cancer

Surgery(2023)10.1016/j.surg.2023.09.046

N/A

0DataRank · unranked

0 citations

Sara Sakowitz, Nikhil Chervu, Corynn Branche, Brian Shuch, Peyman Benharash +2 more

EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba4500

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +15 more

CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells

Molecules(2022)10.3390/molecules27238457

N/A

0DataRank · unranked

14 citations

Hyun Seok Oh, Leila Izzy Jones, Randy Caliliw, Shinji Ohtake, Brian Shuch +2 more

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.270

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Ian M. Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng +15 more

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

European Urology(2024)10.1016/j.eururo.2024.05.012

N/A

0DataRank · unranked

8 citations

Catherine M. Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell V. Meng +16 more

PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps4596

N/A

0DataRank · unranked

10 citations

Se Eun Kim, Viraj A. Master, David F. McDermott, Sabina Signoretti, David Cella +15 more

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.10.022

N/A

0DataRank · unranked

5 citations

Salvatore La Rosa, Tian Zhang, Phillip M. Pierorazio, Laurence Albigès, Kathryn E. Beckermann +19 more

Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5004

N/A

0DataRank · unranked

94 citations

Sandeep Gurram, Munjid Al Harthy, Eric A. Singer, Abhinav Sidana, Brian Shuch +14 more

Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers

Nature Communications(2025)10.1038/s41467-025-65303-z

N/A

0DataRank · unranked

1 citations

Todd A. Johnson, Erika Muraoka, Go Noguchi, Shigekatsu Maekawa, Wataru Obara +48 more

Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cells

Oncogenesis(2020)10.1038/s41389-020-0243-y

N/A

0DataRank · unranked

14 citations

Kay Y. Chong, Tobias M.P. Hartwich, Fangfang Bi, Allyson K. Witham, David Patrick +11 more

Comparative analyses define differences between BHD-associated renal tumour and sporadic chromophobe renal cell carcinoma

EBioMedicine(2023)10.1016/j.ebiom.2023.104596

N/A

0DataRank · unranked

21 citations

Todd A. Johnson, Kazuhiro Maejima, Jisong An, Young-Seok Ju, Hwajin Lee +36 more

Metabolic evaluation of sporadic papillary kidney cancer.

Journal of Clinical Oncology(2012)10.1200/jco.2012.30.5_suppl.377

N/A

0DataRank · unranked

0 citations

Christopher Ricketts, Carole Sourbier, Shinji Tsutsumi, Xiu-ying Zhang, Arie S. Belldegrun +4 more

FH Variant Pathogenicity Promotes Purine Salvage Pathway Dependence in Kidney Cancer

Cancer Discovery(2023)10.1158/2159-8290.cd-22-0874

N/A

0DataRank · unranked

73 citations

Nishma Chakraborty, Nedas Matulionis, Stephanie Hernandez, Daiki Ueno, Michayla E. Gee +6 more

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps402

N/A

0DataRank · unranked

17 citations

Catherine M. Tangen, Abhishek Tripathi, Brian Shuch, Sumanta K. Pal, Pedro C. Barata +9 more

Brian Shuch

Indexed papers

Top data-sharing exemplar

Papers